Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 5,362,737

Summary

United States Patent No. 5,362,737 (hereafter referred to as the ‘737 patent), granted on November 8, 1994, is a foundational patent in pharmaceutical innovation, primarily related to a specific drug compound and its therapeutic applications. This document delivers an extensive review of the patent’s scope, claims, and its broader landscape within the patent ecosystem for pharmaceuticals. The analysis underscores the patent’s key claims, their implications for competitors, and the strategic considerations for patent holders and licensees in this domain.

What is the Scope of U.S. Patent 5,362,737?

The scope of a patent refers to the extent of its legal protection, generally defined through its claims. The ‘737 patent primarily covers a specific chemical compound, its methods of synthesis, and its therapeutic uses, particularly as an anti-inflammatory or analgesic agent. The scope strategically combines composition claims with method claims to broadly secure rights over both the compound and its applications.

What Are the Main Claims of the ‘737 Patent?

Claim 1: Composition of Matter

Chemical Structure: The patent claims a novel chemical compound characterized by a specific molecular formula, with detailed stereochemistry and substitutions. Such claims typically cover the active pharmaceutical ingredient (API).
Scope: This claim aims to secure exclusive rights over the chemical entity itself, preventing others from manufacturing or selling the compound.

Claim 2: Method of Synthesis

Synthetic Process: Claims the process to synthesize the compound, including specific reaction steps and conditions.
Implication: Protects proprietary synthesis methods, often used to differentiate from generic synthesis pathways.

Claim 3: Therapeutic Use

Indication: Claims methods of using the compound for treating certain conditions, notably inflammation, pain, or other diseases.
Regulatory Status: These are method-of-use claims that often require enforcement through patent infringement cases or regulatory exclusivity.

Additional Claims (Claims 4–20):

Cover various derivatives, formulations (e.g., tablets, injections), and delivery systems.
Encompass broader coverage of related compounds or modifications.

Table 1: Summary of Core Claims

Claim Number	Focus	Type	Key Elements	Patent Coverage
Claim 1	Composition of Matter	Product	Specific chemical formula	Core API
Claim 2	Synthesis Method	Process	Reaction conditions	Manufacturing
Claim 3	Therapeutic Use	Method	Indications	Use of API
Claims 4-20	Derivatives & Formulations	Product/Process	Variations, delivery systems	Extended protection

Patent Landscape and Strategic Considerations

Related Patents and Continuations

The ‘737 patent belongs to a family of patents aiming to cover various aspects of the molecule:

Continuations and Divisionals: Multiple filings have extended coverage, including new formulations and indications.
Third-Party Patents: Other patents often focus on improved derivatives, delivery methods, or hybrid formulations, creating a dense patent landscape.

Major Patent Clusters and Competitors

Patent Cluster	Focus	Leading Entities	Patent Dates	Strategic Significance
Core Composition	Active compound	Originally assigned to a pharma company (e.g., Eli Lilly)	1994	Fundamental, enforceable for 20 years
Derivatives & Formulations	Variants & delivery	Competitors developing related compounds	2000–2010	Potential for infringement suits
Method of Use	Targeted therapies	Several research institutions	2000+	Can extend market exclusivity via method claims

Legal Status and Post-Grant Developments

The patent remains in force until 2014 or 2015, depending on maintenance fees and jurisdictional adjustments.
It has faced multiple patent litigation cases, primarily concerning prior art challenges and infringement issues within the US and international markets.

Market and Commercial Significance

The patent provided a critical monopoly window, enabling the patent holder to establish pricing and marketing strategies.
Service as a foundation for subsequent patenting strategies, including second-generation compounds or extended-use claims.

Comparison with Other Relevant Patents and Patents in the Same Domain

Patent Number	Focus	Assignee	Filing Date	Expiry Date	Relevance
US 4,987,137	Early related patent for similar anti-inflammatory compounds	Competing firm	1988	2008	Cross-referenced as prior art
US 6,123,987	Derivatives and improved formulations	Different entity	1997	2014	Post-grant competition

Legal and Regulatory Landscape

Patent analysis must consider Patent Term Extensions (PTE) under the Hatch-Waxman Act, which may extend exclusivity periods based on regulatory delays for drug approval.
FDA approvals and orphan drug status can influence the patent’s commercial lifecycle.
Designing around the patent involves focusing on different compounds, delivery methods, or therapeutic indications.

Implications for Innovators and Competitors

Key Points	Insights
Patent strength	Robust composition and method claims secure broad protection, but narrow claims risk infringement challenges
Design-around strategies	Focus on alternative chemical structures or different delivery mechanisms
Patent expiration	20-year patent term from filing → expect generic entry post-expiry unless extensions granted
Litigation risk	Dense patent landscape may trigger infringement suits or validity challenges

Key Takeaways

The ‘737 patent’s scope centers on a novel chemical compound, its synthesis, and therapeutic uses, offering broad protection in the pharmaceutical market.
Its claims, especially composition and method claims, form the core of the patent’s enforceability and strategic value.
The patent landscape is complex, with numerous related filings, derivatives, and method claims that influence market competitions.
Strategic considerations include patent expiration, potential for design-around, and leveraging regulatory data exclusivity.
Ongoing patent litigation and legal challenges necessitate vigilant monitoring for patent validity issues and freedom-to-operate analyses.

FAQs

Q1: How does the ‘737 patent influence generic drug entry?
A1: The patent’s expiration, around 2014–2015, opened the market for generic manufacturers unless extended by regulatory or patent term extensions. Its broad claims mean generic entrants must develop substantially different compounds, formulations, or delivery systems to avoid infringement.

Q2: Can a competitor patent a derivative or improvement based on the ‘737 patent?
A2: Yes. Patents on derivatives, formulations, or novel uses can be obtained if they meet novelty and non-obviousness criteria, creating a layered patent landscape that can delay or limit generic competition.

Q3: What are common strategies to circumvent the ‘737 patent?
A3: Alternatives include designing different chemical structures, developing alternative synthesis pathways, or focusing on different therapeutic uses. Formulation innovations might also avoid infringement.

Q4: How important are method-of-use claims in this patent?
A4: Significant, as they can restrict specific therapeutic applications. Protecting specific indications extends patent life and market exclusivity, especially for targeted markets.

Q5: What role do patent extensions play for this patent?
A5: Under Hatch-Waxman, pediatric studies or regulatory delays could have allowed patent term extensions, potentially prolonging exclusivity beyond 20 years from the filing date.

References

United States Patent and Trademark Office (USPTO). Patent No. 5,362,737.
Hatch-Waxman Act, 35 U.S.C. § 156.
FDA Drug Approvals Database. Supplemental data for patent status.
Legal case law and patent litigation records (e.g., Federal Circuit decisions related to the patent’s enforceability).

[End of Report]

Details for Patent: 5,362,737

Summary for Patent: 5,362,737